Individualizing Therapy in the Management of
Rheumatoid Arthritis: A Closer Look at Emerging
Therapeutic Options


A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Lilly USA LLC

Description:
According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from Rheumatoid arthritis (RA) in the United States. Rheumatoid arthritis varies greatly from patient to patient, and with each patient it varies over time. Diagnosis is done through examination to including x-rays, ultrasounds, and blood testing for certain indications and to rule out other possible causes for the symptoms. There is no cure for RA, and the goal of treatment is to control the pain, especially during flair ups, and to prevent joint damage. However, even with all of the currently available non-biologic and biologic therapies, only about 1/3 of patients treated for RA ever achieve clinical remission. The remaining patients can experience continuous disease progression and disability. In addition, many patients will have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Consequently, the patient’s health-related quality of life may continue to be significantly reduced. Fortunately, new and emerging treatment strategies may offer additional therapeutic options to address the unmet needs of these patients. Clinicians have recently been equipped with more treatment options, including IL-6 receptor antagonists, and several more have just completed late stage clinical trials and are currently undergoing regulatory review.

Upon Completion of this activity, participants will be able to:

  • Review the mechanisms of action, efficacy and safety of new and emerging therapies in the management of Rheumatoid Arthritis (RA) for achieving individualized treatment goals

  • Explain the roles of janus kinases (JAKs) and interleukins (ILs) in the pathogenesis of rheumatoid arthritis (RA) and their relationship to local inflammation, cartilage damage, and bone erosion

  • Analyze the pharmacokinetic and pharmacodynamic differences across the JAK inhibitors in patients with RA

  • Customize individualized treatment regimens for RA based on repeated assessment of disease activity, functional status, treatment response, and other patient-specific risks

  • Explore strategies to monitor and manage adverse events associated with emerging JAK inhibitors in RA management in order to improve patient adherence

  • Examine the direct and indirect costs associated with RA management and outline the data that managed care providers need to make informed decisions about RA treatment
     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

Dr. Owens serves as a consultant AbbVie, Biogen, Novartis and Roche. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Association of Managed Care Nurses (AAMCN) and the National Association of Managed Care Physicians (NAMCP). NAMCP is accredited by the ACCME to provide continuing medical education to physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Lilly USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue